{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Melanoma",
    "query": {
      "condition": "Cervical Melanoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 348,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Melanoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T12:11:17.095Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03991741",
      "title": "Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Locally Advanced Refractory/Recurrent Melanoma",
        "Metastatic Head and Neck Cancer",
        "Locally Advanced Refractory/Recurrent Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Autologous Tumor Infiltrating Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Interleukin 2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gregory Daniels",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-10-07",
      "completion_date": "2023-01-26",
      "has_results": true,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03991741"
    },
    {
      "nct_id": "NCT05576077",
      "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Uveal Melanoma",
        "Cutaneous Melanoma",
        "Non-Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TBio-4101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Turnstone Biologics, Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 31,
      "start_date": "2023-01-17",
      "completion_date": "2025-02-24",
      "has_results": false,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 11,
      "location_summary": "Irvine, California • Hollywood, Florida • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05576077"
    },
    {
      "nct_id": "NCT05039801",
      "title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Endometrial Carcinoma",
        "Advanced Head and Neck Squamous Cell Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Melanoma",
        "Advanced Ovarian Clear Cell Adenocarcinoma",
        "Chondrosarcoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Recurrent Ovarian High Grade Serous Adenocarcinoma",
        "Refractory Endometrial Carcinoma",
        "Refractory Head and Neck Squamous Cell Carcinoma",
        "Refractory Melanoma",
        "Refractory Ovarian Clear Cell Adenocarcinoma",
        "Refractory Ovarian High Grade Serous Adenocarcinoma",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Glutaminase-1 Inhibitor IACS-6274",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2021-09-30",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039801"
    },
    {
      "nct_id": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Non-small-cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-07826390",
          "type": "DRUG"
        },
        {
          "name": "sasanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SOC (anti-PD-1 + platinum -based chemo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-09-06",
      "completion_date": "2025-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06546553"
    },
    {
      "nct_id": "NCT01351103",
      "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "BRAF Mutant Colorectal Cancer",
        "Melanoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Cancer",
        "Cervical Squamous Cell Cancer",
        "Esophageal Squamous Cell Cancer",
        "Lung Squamous Cell Cancer"
      ],
      "interventions": [
        {
          "name": "LGK974",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2011-12-01",
      "completion_date": "2024-06-17",
      "has_results": false,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01351103"
    },
    {
      "nct_id": "NCT01522820",
      "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma",
        "Anaplastic Oligoastrocytoma",
        "Anaplastic Oligodendroglioma",
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "Glioblastoma",
        "Hormone-Resistant Prostate Cancer",
        "Metastatic Prostate Carcinoma",
        "Metastatic Renal Cell Cancer",
        "Recurrent Adult Brain Neoplasm",
        "Recurrent Bladder Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Esophageal Carcinoma",
        "Recurrent Gastric Carcinoma",
        "Recurrent Hepatocellular Carcinoma",
        "Recurrent Lung Carcinoma",
        "Recurrent Melanoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Resectable Hepatocellular Carcinoma",
        "Sarcoma",
        "Stage IA Breast Cancer",
        "Stage IA Ovarian Cancer",
        "Stage IA Uterine Corpus Cancer",
        "Stage IB Breast Cancer",
        "Stage IB Ovarian Cancer",
        "Stage IB Uterine Corpus Cancer",
        "Stage IC Ovarian Cancer",
        "Stage II Uterine Corpus Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIA Lung Carcinoma",
        "Stage IIA Ovarian Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIB Esophageal Cancer",
        "Stage IIB Lung Carcinoma",
        "Stage IIB Ovarian Cancer",
        "Stage IIB Skin Melanoma",
        "Stage IIC Ovarian Cancer",
        "Stage IIC Skin Melanoma",
        "Stage IIIA Breast Cancer",
        "Stage IIIA Esophageal Cancer",
        "Stage IIIA Lung Carcinoma",
        "Stage IIIA Ovarian Cancer",
        "Stage IIIA Skin Melanoma",
        "Stage IIIA Uterine Corpus Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIB Esophageal Cancer",
        "Stage IIIB Ovarian Cancer",
        "Stage IIIB Skin Melanoma",
        "Stage IIIB Uterine Corpus Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IIIC Esophageal Cancer",
        "Stage IIIC Ovarian Cancer",
        "Stage IIIC Skin Melanoma",
        "Stage IIIC Uterine Corpus Cancer",
        "Stage IV Bladder Urothelial Carcinoma",
        "Stage IV Esophageal Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Prostate Cancer",
        "Stage IV Skin Melanoma",
        "Stage IVA Uterine Corpus Cancer",
        "Stage IVB Uterine Corpus Cancer"
      ],
      "interventions": [
        {
          "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2012-03",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-10-04",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522820"
    },
    {
      "nct_id": "NCT04987996",
      "title": "GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "GR-MD-02",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-07-01",
      "completion_date": "2031-07-01",
      "has_results": false,
      "last_update_posted_date": "2023-06-06",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04987996"
    },
    {
      "nct_id": "NCT00975520",
      "title": "Neurotropic Melanoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Observation",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Melanoma and Skin Cancer Trials Limited",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2009-09",
      "completion_date": "2023-03",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00975520"
    },
    {
      "nct_id": "NCT06270082",
      "title": "Study of IK-595 in RAS- or RAF-altered Advanced Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Malignant Melanoma",
        "Ras (Kras or Nras) Gene Mutation",
        "BRAF Gene Mutation",
        "CRAF Gene Mutation",
        "Non-Small Cell Lung Carcinoma",
        "Thyroid Carcinoma",
        "Gliomas, Malignant"
      ],
      "interventions": [
        {
          "name": "IK-595",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2023-12-18",
      "completion_date": "2025-09-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Orange, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06270082"
    },
    {
      "nct_id": "NCT02475213",
      "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Enoblituzumab Schedule 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enoblituzumab Schedule 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "retifanlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2015-07",
      "completion_date": "2021-08-18",
      "has_results": true,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-06-25T12:11:17.095Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Newark, Delaware • Jacksonville, Florida + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475213"
    }
  ]
}